Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.
The FDA has approved a second dosing schedule for the PD-1 inhibitor nivolumab across all of the PD-1 inhibitor's monotherapy indications. This now allows physicians to prescribe the new dosing schedule of 480 mg of nivolumab every 4 weeks.
Nivolumab is currently approved as a single agent for advanced melanoma, advanced non-small cell lung cancer, advanced renal cell carcinoma, metastatic urothelial carcinoma, Hodgkin lymphoma, and advanced head and neck squamous cell carcinoma.
For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.